PET volume, glycolytic activity predict NSCLC local recurrence

November 12, 2012

By characterizing non-small cell lung cancer (NSCLC) tumors through glycolytic activity and FDG-PET volume after stereotactic body radiation therapy (SBRT), clinicians may be able to detect which tumors are likely to recur, according to a study presented at last week's American Society for Radiation Oncology (ASTRO) meeting.

If these tumors are identified, earlier and more effective treatment can be crafted for the benefit of these patients, researchers from Oakland University William Beaumont School of Medicine concluded.